Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Chenghao Shao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2429-7796; OpenAlex author ID A5035698665, A5070796699. Sources: OpenAlex.

Their work

Papers
33 (first author 3, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
116
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: 4 papers · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 33

  1. Intratumoral Enterobacter hormaechei drives gemcitabine resistance in pancreatic cancer via cdd L-mediated drug inactivation. Co-author DOI 10.1002/imt2.70126↗
  2. Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer. Co-author DOI 10.1038/s41467-026-73702-z↗
  3. Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.09.043↗
  4. Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study. Last author DOI 10.21037/jgo-2025-1-1022↗
  5. PLXDC1+ Tumor-Associated Pancreatic Stellate Cells Promote Desmoplastic and Immunosuppressive Niche in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202415756↗
  6. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  7. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  8. Identifying Liver Metastasis-Related Genes Through a Coexpression Network to Construct a 5-Gene Model for Predicting Pancreatic Ductal Adenocarcinoma Patient P… Last author DOI 10.1097/mpa.0000000000002229↗
  9. PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-022-02609-y↗
  10. Development of a Gene Risk Signature for Patients of Pancreatic Cancer. Last author DOI 10.1155/2022/4136825↗
  11. The structure elucidation of novel arabinogalactan LRP1-S2 against pancreatic cancer cells growth in vitro and in vivo. Co-author DOI 10.1016/j.carbpol.2021.118172↗
  12. SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway. Last author DOI 10.1038/s41420-021-00779-4↗
  13. Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysi… Last author DOI 10.21037/gs-21-151↗
  14. Downregulated F-Box/LRR-Repeat Protein 7 Facilitates Pancreatic Cancer Metastasis by Regulating Snail1 for Proteasomal Degradation. Last author DOI 10.3389/fgene.2021.650090↗
  15. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. First author DOI 10.1093/carcin/bgz086↗
  16. Network-based integration of mRNA and miRNA profiles reveals new target genes involved in pancreatic cancer. Co-author DOI 10.1002/mc.22920↗
  17. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. Co-author DOI 10.1016/j.carbpol.2018.10.008↗
  18. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  19. Long non-coding RNA CUDR promotes malignant phenotypes in pancreatic ductal adenocarcinoma via activating AKT and ERK signaling pathways. Last author DOI 10.3892/ijo.2018.4574↗
  20. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Co-author DOI 10.1038/onc.2016.306↗
  21. HIF1/2α mediates hypoxia-induced LDHA expression in human pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.15266↗
  22. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  23. Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression. Co-author DOI 10.1038/ncomms8184↗
  24. miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Co-author DOI 10.1159/000373995↗
  25. Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Co-author DOI 10.1186/s12943-015-0447-5↗
  26. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  27. miR-208-induced epithelial to mesenchymal transition of pancreatic cancer cells promotes cell metastasis and invasion. First author DOI 10.1007/s12013-013-9805-3↗
  28. Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer. First author DOI 10.1007/s13277-014-2564-y↗
  29. miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. Co-author DOI 10.1016/j.febslet.2014.10.004↗
  30. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2011.02.086↗
  31. MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. Last author DOI 10.1016/j.febslet.2010.11.039↗
  32. Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling. Co-author DOI 10.1042/bj20110297↗
  33. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Last author DOI 10.1093/carcin/bgr105↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xing Liang · 8 shared papers, 2018–2023 · strength 1.10
  2. Ju‐Dong Li · 5 shared papers, 2022–2026 · strength 1.09
  3. Xianjun Yu · 6 shared papers, 2015–2026 · strength 0.71
  4. Kan Ding · 5 shared papers, 2011–2026 · strength 0.63
  5. Zhiping Fu · 4 shared papers, 2021–2023 · strength 0.59
  6. Si Shi · 3 shared papers, 2023–2026 · strength 0.57
  7. An‐An Liu · 6 shared papers, 2014–2023 · strength 0.54
  8. Ting Niu · 2 shared papers, 2026 · strength 0.53
  9. Youqiong Ye · 2 shared papers, 2025–2026 · strength 0.45
  10. Yanhua Du · 2 shared papers, 2025–2026 · strength 0.45
  11. Duowu Zou · 2 shared papers, 2025–2026 · strength 0.45
  12. Anan Liu · 4 shared papers, 2014–2023 · strength 0.40
  13. Jin Xu · 3 shared papers, 2018–2025 · strength 0.40
  14. Rong Tang · 2 shared papers, 2023–2026 · strength 0.38
  15. Qiong Du · 2 shared papers, 2023–2026 · strength 0.38
  16. Xiangui Hu · 7 shared papers, 2011–2018 · strength 0.30
  17. Jun‐Feng Peng · 1 shared paper, 2026 · strength 0.29
  18. Liang V. Tang · 2 shared papers, 2021 · strength 0.27
  19. Renyi Qin · 3 shared papers, 2015–2025 · strength 0.26
  20. Xiao-Yu Yin · 1 shared paper, 2026 · strength 0.24
  21. Liquan Jin · 1 shared paper, 2026 · strength 0.24
  22. Gang Jin · 5 shared papers, 2014–2015 · strength 0.23
  23. Yao Zhang · 1 shared paper, 2026 · strength 0.23
  24. Hamid Alinejad‐Rokny · 1 shared paper, 2025 · strength 0.22
  25. Chen Liu · 2 shared papers, 2015–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.